Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
308
datasets available to search
ShareScore release 0.9.0
Dataset results
308 results for “cannabidiol”
Drug Interaction Study Data from the Drug Approval Package for Epidiolex (Cannabidiol)
<p>Data from the drug interaction studies reported in the drug approval package for Epidiolex (cannabidil), U.S. Food and Drug Administration: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000TOC.cfm.</p> <p>The data was manually extracted by a trained pharmacist from the PDF documents uploaded to drugs@fda for Epidolex drug approval package. The data extraction was reviewed for quality by an expert in pharamacology and natural product-drug interactions.</p>
Time series of epileptic seizures in a 8yo male on a cannabidiol trial
<p>Time series of epileptic seizures in a 8yo male with idiopathic catastrophic epilepsy (probably of mitochondrial origin) in a cannabidiol (CBD) trial.</p> <p>The data are of <strong>observed seizures </strong>during each day by the patient's parents and caregivers and thus are not exact values for total daily seizure activity; the values in this dataset are best considered a lower bound. However, observation effort was essentially constant over the time series, so the data likely reflect overall trends even though precise daily seizure counts are not available.</p> <p>The time series includes a 21-day baseline period and a 36-day trial period. The CBD was administered via g-tube in an olive oil base. Dosage was approximately 7.5 mg/kg/day for two weeks, and approximately 8 mg/kg/day for three weeks.</p> <p>Each 1ml of oil contained 10.00mg of total CBD and 0.42mg of total THC, for a CBD:THC ratio of approximately 20:1 (analysis by HPLC).</p> <p><strong><em>Data Dictionary</em></strong></p> <ul> <li><strong>Date</strong>: YYYY-MM-DD</li> <li><strong>Tonic</strong>: tonic seizure count (http://www.epilepsy.com/learn/types-seizures/tonic-seizures)</li> <li><strong>Tonic-Clonic</strong>: tonic-clonic (aka "grand mal") seizure count (http://www.epilepsy.com/learn/types-seizures/tonic-clonic-seizures)</li> <li><strong>Spasms</strong>: myoclonic seizure count (http://www.epilepsy.com/learn/types-seizures/myoclonic-seizures)</li> <li><strong>Total</strong>: total number of seizures (sum of above)</li> <li><strong>Notes</strong>: notes by parents</li> </ul>
3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract
<h2>Abstract</h2> <div>The therapeutic potential of <span>Cannabis sativa</span> L. extract has gained significant attention due to its diverse medical applications. Sublingual administration remains a common delivery method of cannabinoids; however, challenges often arise due to the inconvenient form of the extract and its taste. To address these issues, a novel bigel formulation was developed, combining water and oil phases to enhance stability and bioavailability. This formulation incorporates a cannabidiol-rich hemp extract, hyaluronic acid for its moisturizing properties, and a taste-masking agent to improve patient compliance and comfort. Using a standardized hemp extract rich in cannabinoids and a well-characterized terpene profile, the printability of the bigels was evaluated through 3D printing technology. A printout with known cannabidiol (CBD) and cannabidiolic acid (CBDA) content of 11.613 mg ± 0.192 of CBD and 4.732 mg ± 0.280 of CBDA in the printout was obtained. In addition, the release profile of CBD and CBDA was evaluated to determine the delivery efficiency of the active ingredient—dissolved active ingredient levels ranged from 74.84% ± 0.50 to 80.87% ± 3.20 for CBD and from 80.84 ± 1.33 to 98.31 ± 1.70 for CBDA depending on the formulation. Rheological studies were conducted to evaluate the viscosity of the bigels under varying temperature conditions, ensuring their stability and usability. Findings suggest that this 3D-printed bigel formulation could significantly enhance the delivery of cannabis extracts, offering a more convenient and effective therapeutic option for patients. This research underscores the importance of innovation in cannabinoid therapies and paves the way for further advancements in personalized medicine.</div>
Transcriptome Analysis of Cisplatin, Cannabidiol, and Intermittent Serum Starvation Alone and in Various Combinations on Colorectal Cancer Cells
<p>* See README file for the description of data files available in this repository</p> <p>1. Study Description:</p> <p>Platinum-derived chemotherapy medications are often combined with other conventional therapies for treating different tumours, including colorectal cancer. However, the development of drug resistance and multiple adverse effects remain common in clinical settings. Thus, there is a necessity to find novel treatments and drug combinations that could effectively target colorectal cancer cells and lower the probability of disease relapse. To find potential synergistic interaction, we designed multiple different combinations between cisplatin, cannabidiol, and intermittent serum starvation on colorectal cancer cell lines. Based on the cell viability assay, we found that combinations between cannabidiol and intermittent serum starvation, cisplatin, and intermittent serum starvation, as well as cisplatin, cannabidiol and intermittent serum starvation can work in a synergistic fashion on different colorectal cancer cell lines. Furthermore, we analyzed differentially expressed genes and affected pathways in colorectal cancer cell lines to understand further the potential molecular mechanisms behind the treatments and their interactions. We found that synergistic interaction between cannabidiol and intermittent serum starvation can be related to changes in the transcription of genes responsible for cell metabolism and cancer’s stress pathways. Moreover, when we added cisplatin to the treatments, there was a strong enrichment of genes taking part in G2/M cell cycle arrest and apoptosis.</p> <p> </p> <p>2. Bioinformatics workflow:</p> <p>Initial quality control was conducted using FastQC v0.11.9 https://www.bioinformatics.babraham.ac.uk/projects/fastqc/. Sequencing reads were trimmed of adapter sequences and low-quality bases using Trimmomatic. Trimmed sequence files were examined with FastQC to verify the trimming results. Trimmed sequencing reads were mapped to Human genome (GRCh37, Ensembl) downloaded from Illumina iGenome website (<a href="https://support.illumina.com/sequencing/sequencing_software/igenome.html">https://support.illumina.com/sequencing/sequencing_software/igenome.html</a>). Mapping was done using splice aware aligner HISAT2 2.1.0. Alignment files in SAM format were converted to BAM, sorted and indexed with samtools v.1.3.1. Mapping quality and statistics were collected with QualiMap software package v.2.2.2 <a href="http://qualimap.conesalab.org/">http://qualimap.conesalab.org/</a> The counts if reads mapping to features (genes) were counted using FeatureCounts v.2.0.1 software.</p> <p>Data exploration, visualization and statistical comparisons were conducted using R language version 4.2.2. Pair-wise comparisons between experimental groups were done with DESeq2 v.2.1.36 as described in the package manual. To decrease computational time, only the genes with at least 5 reads across 3 samples were kept in the analysis. In addition to hard threshold filtering mentioned above, DESeq2 implements independent filtering based on mean of normalized count as a filter statistic.</p> <p>We used hierarchical clustering (HC) and principal components analysis (PCA) to investigate the relationship between samples and detect potential outliers. Prior to HC and PCA analysis, DESeq2 normalized values underwent variance stabilizing transformation with using vst() function from DESeq2. HC was done using hclust() function implemented in R, with the clustering method set as “complete” for the matrices of sample-to-sample distances, and “Ward.D2” in case of the sample and gene clustering based on top 500 most variable genes. The distance measure in HC analysis was set to “euclidean”. Principal components analysis (PCA), applied to top 500 highly variable genes, was conducted using prcomp() function implemented in R with default options.</p> <p>Differentially expressed genes (DEGs) were detected with DESeq2 function results() with default options. DESeq2 uses Wald test to determine significantly changed genes between groups. The independent filtering option was set to TRUE with alpha threshold (adjusted p-value) kept at 0.1. Multiple comparison adjustment was done using Bejamini-Hochberg procedure.</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p>
The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy
ClinicalTrials.gov study NCT04672252. IPD Sharing: YES. Countries: 1. Publications: 2.
Co-Dispersion Delivery Systems with Solubilizing Carriers Improving the Solubility and Permeability of Cannabinoids (Cannabidiol, Cannabidiolic Acid, and Cannabichromene) from Cannabis sativa (Henola Variety) Inflorescences
<p>Article, Dataset for article</p> <p> </p> <h2>Abstract</h2> <div>Cannabinoids: cannabidiol (CBD), cannabidiolic acid (CBDA), and cannabichromene (CBC) are lipophilic compounds with limited water solubility, resulting in challenges related to their bioavailability and therapeutic efficacy upon oral administration. To overcome these limitations, we developed co-dispersion cannabinoid delivery systems with the biopolymer polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (Soluplus) and magnesium aluminometasilicate (Neusilin US2) to improve solubility and permeability. Recognizing the potential therapeutic benefits arising from the entourage effect, we decided to work with an extract instead of isolated cannabinoids. <span>Cannabis sativa</span> inflorescences (Henola variety) with a confirming neuroprotective activity were subjected to dynamic supercritical CO<sub>2</sub> (scCO<sub>2</sub>) extraction and next they were combined with carriers (1:1 mass ratio) to prepare the co-dispersion cannabinoid delivery systems (HiE). In vitro dissolution studies were conducted to evaluate the solubility of CBD, CBDA, and CBC in various media (pH 1.2, 6.8, fasted, and fed state simulated intestinal fluid). The HiE-Soluplus delivery systems consistently demonstrated the highest dissolution rate of cannabinoids. Additionally, HiE-Soluplus exhibited the highest permeability coefficients for cannabinoids in gastrointestinal tract conditions than it was during the permeability studies using model PAMPA GIT. All three cannabinoids exhibited promising blood-brain barrier (BBB) permeability (P<sub>app</sub> higher than 4.0 × 10<sup>−6</sup> cm/s), suggesting their potential to effectively cross into the central nervous system. The improved solubility and permeability of cannabinoids from the HiE-Soluplus delivery system hold promise for enhancement in their bioavailability.</div> <div> <div> <div>Keywords: </div> <a href="https://www.mdpi.com/search?q=cannabidiol">cannabidiol</a>; <a href="https://www.mdpi.com/search?q=cannabidiolic+acid">cannabidiolic acid</a>; <a href="https://www.mdpi.com/search?q=cannabichromene">cannabichromene</a>; <a href="https://www.mdpi.com/search?q=cannabis">cannabis</a>; <a href="https://www.mdpi.com/search?q=solubility">solubility</a>; <a href="https://www.mdpi.com/search?q=permeability">permeability</a></div> </div>
MD simulation trajectory of cannabidiol in the cannabinoid type 1 receptor
<p>MD simulation trajectory of cannabidiol in the presence of an orthosteric THC and Rimonabant in the CB1R active and inactive conformations respectively. The protein–ligand complexes were inserted in a POPC lipid bilayer and solvated in a TIP3 water box with Na+ and Cl- ions. Simulations were run with NAMD 2.9 software using periodic boundary conditions and Particle Mesh Ewald (PME) for long-range electrostatics. Total production time for the inactive and active receptor conformations were 25 ns and 50 ns respectively.<br> </p>
Characterization of the biochemical and behavioral effects of cannabidiol: implications for migraine
<p>This dataset comprises the findings obtained in the study aimed at investigating the anti-migraine effects of cannabidiol (CBD) in the migraine rat models based by nitroglycerin (NTG) administration. We assayed CBD distribution (15 and 30mg/kg, i.p.) in plasma and in cranial areas related to migraine pain in male Sprague Dawley rats treated chronically (5 days). Successively, we tested CBD activity on the behavioral and biochemical effects induced in the acute and the chronic migraine animal models by NTG administration. In the acute migraine model, rats received CBD (15 mg or 30 mg/kg, i.p) 3 h after NTG (10 mg/kg i.p.) or vehicle injection. In the chronic migraine model, rats were treated with CBD and NTG every other day over nine days with the following doses: CBD 30 mg/kg i.p., NTG 10 mg/kg i.p. We evaluated behavioral parameters with the open field and the orofacial formalin tests. We explored the fatty acid amide hydrolase (FAAH) gene expression, cytokines mRNA and protein levels in selected brain areas and CGRP serum level. CBD levels in the meninges, trigeminal ganglia, cervical spinal cord, medulla pons, and plasma were higher 1 h after the last treatment than after 24 h, suggesting that CBD penetrates but does not accumulate in these tissues. In the acute model, CBD significantly reduced NTG-induced trigeminal hyperalgesia and CGRP and cytokine mRNA levels in peripheral and central sites. In the chronic model, CBD caused only a significant decrease in NTG-induced IL-6 protein levels in the medulla-pons, and trigeminal ganglion. It also reduced CGRP serum levels. In both experimental conditions, there was no modulation of anxiety, motor/exploratory behavior, or grooming.</p> <p>The in vivo and ex vivo assessments were:</p> <p>1) mRNA expression levels: CGRP, SP, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and FAAH in cervical spinal cord, medulla-pons and trigeminal ganglia. mRNA levels were measured by rt-PCR. All samples were assayed in triplicate and gene expression levels were calculated according to 2−∆∆Ct = 2− (∆Ct gene − ∆Ct housekeeping gene) formula by using Ct (cycle threshold) values.</p> <p>2) Central and peripheral CBD levels were quantified in rat brain tissue and plasma samples using a previously proven online solid phase extraction (SPE) high-performance liquid chromatography (HPLC) method coupled with tandem mass spectrometry (MS/MS).</p> <p>3) Cytokines and CGRP protein levels were measured using the ELISA kits. The samples' measured absorbance was compared to a standard curve using a microplate reader.</p> <p>4) Behavior Formalin test= the face rubbing was measured counting the seconds the animal spent grooming the injected area (seconds).</p> <p>5) open field test= distance (expressed in meters) travelled in the apparatus; time spent (expressed in seconds) in the center of the apparatus; number of rearing; time spent in grooming behavior (expressed in seconds).</p> <p>Results in brief</p> <p>These data show that CBD modulates migraine-related nociceptive transmission, likely via a complex signaling mechanism involving different pathways.</p>
An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
ClinicalTrials.gov study NCT01610700. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Interaction Between Cannabidiol, Meal Ingestion, and Liver Function
ClinicalTrials.gov study NCT04971837. IPD Sharing: NO. Countries: 1. Publications: 1.
Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury
ClinicalTrials.gov study NCT04586712. IPD Sharing: NO. Countries: 1. Publications: 0.
An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
ClinicalTrials.gov study NCT01610713. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Cannabidiol for ASD Open Trial
ClinicalTrials.gov study NCT03900923. IPD Sharing: YES. Countries: 1. Publications: 0.
Oral Cannabidiol for Opioid Withdrawal
ClinicalTrials.gov study NCT04238754. IPD Sharing: NO. Countries: 1. Publications: 0.
The Effect of Cannabidiol in Learning and Memory of Adults
ClinicalTrials.gov study NCT06074172. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
ClinicalTrials.gov study NCT02224690. IPD Sharing: Not stated. Countries: 3. Publications: 5.
Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine
ClinicalTrials.gov study NCT04192370. IPD Sharing: NO. Countries: 1. Publications: 1.
Cannabidiol as a Treatment for AUD Comorbid With PTSD
ClinicalTrials.gov study NCT03248167. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
ClinicalTrials.gov study NCT01610687. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
ClinicalTrials.gov study NCT06192589. IPD Sharing: YES. Countries: 1. Publications: 11.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.